Phase I Study of CTL Anti-DP Infusion Post-hematopoietic Stem Cell Transplantation — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Phase I Study of CTL Anti-DP Infusion Post-hematopoietic Stem Cell Transplantation — Stella

Recruiting

Back to Haematologic Disease trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

France

Chu de Nantes, Nantes

Key details

Phase

Early testing

Sponsor

Nantes University Hospital

Collaborators

Institut National de la Santé Et de la Recherche Médicale, France

Enrollment target

~6 participants

Started

February 2020

Primary completion

July 2027

Age range

18 Years – 75 Years

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov